Adaptive Biotechnologies Corp
NASDAQ:ADPT

Watchlist Manager
Adaptive Biotechnologies Corp Logo
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Watchlist
Price: 4.69 USD 7.32% Market Closed
Market Cap: 692.2m USD
Have any thoughts about
Adaptive Biotechnologies Corp?
Write Note

Adaptive Biotechnologies Corp
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Adaptive Biotechnologies Corp
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Other Current Liabilities
$51.9m
CAGR 3-Years
-13%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Other Current Liabilities
$2.7B
CAGR 3-Years
23%
CAGR 5-Years
23%
CAGR 10-Years
15%
Danaher Corp
NYSE:DHR
Other Current Liabilities
$1.6B
CAGR 3-Years
-4%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Other Current Liabilities
$431.7m
CAGR 3-Years
10%
CAGR 5-Years
15%
CAGR 10-Years
11%
Agilent Technologies Inc
NYSE:A
Other Current Liabilities
$524m
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
1%
IQVIA Holdings Inc
NYSE:IQV
Other Current Liabilities
$2.3B
CAGR 3-Years
4%
CAGR 5-Years
16%
CAGR 10-Years
15%
No Stocks Found

Adaptive Biotechnologies Corp
Glance View

Market Cap
692.1m USD
Industry
Life Sciences Tools & Services

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.

ADPT Intrinsic Value
6.89 USD
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Adaptive Biotechnologies Corp's Other Current Liabilities?
Other Current Liabilities
51.9m USD

Based on the financial report for Sep 30, 2024, Adaptive Biotechnologies Corp's Other Current Liabilities amounts to 51.9m USD.

What is Adaptive Biotechnologies Corp's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
-3%

Over the last year, the Other Current Liabilities growth was -6%. The average annual Other Current Liabilities growth rates for Adaptive Biotechnologies Corp have been -13% over the past three years , -3% over the past five years .

Back to Top